Clinical trials: Prostate Cancer Stage
Metastatic Castration-Resistant Prostate Cancer
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
- Trial name
- NCT06629779
- Testing
- PF-06821497, Enzalutamide
- Where
- 231 sites in United States, Argentina and 25 more
- Volunteers
- 900 people
- Sponsor
- Pfizer
Prostate Cancer
A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer
In this study, up to 21 patients with metastatic prostate cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels.
- Trial name
- UV1/hTERT2012P (NCT01784913)
- Testing
- UV1 synthetic peptide vaccine and GM-CSF
- Where
- Norway
- Volunteers
- 22 people
- Sponsor
- Ultimovacs ASA
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate
- Trial name
- ARROW (NCT03939689)
- Testing
- I-131-1095, Enzalutamide
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
MCRPC
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating the efficacy and safety of HC-1119 soft capsules versus placebo in mCRPC patients who have failed or become intolerant to the…
- Trial name
- NCT03851640
- Testing
- HC-1119
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Prostatic Neoplasms, Castration-Resistant
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
This is a Phase 1, open-label, international, dose escalation study to evaluate the safety of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) in men with PSMA-positive prostate cancer who have and have not had prior exposure to…
- Trial name
- NCT04597411
- Testing
- 225^Ac-PSMA-617, 68^Ga-PSMA-11
- Where
- 2 sites in Australia, South Africa
- Volunteers
- 101 people
- Sponsor
- Endocyte
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Metastatic Castration-Sensitive Prostate Cancer
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants…
- Trial name
- EvoPAR-PR01 (NCT06120491)
- Testing
- Saruparib, Abiraterone Acetate, Darolutamide
- Where
- 322 sites in United States, Australia and 22 more
- Volunteers
- 1,898 people
- Sponsor
- AstraZeneca
Prostate Cancer
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have…
- Trial name
- NCT00089856
- Testing
- Immunotherapy with allogeneic prostate vaccine, Chemotherapy (Taxotere and prednisone)
- Where
- 126 sites in United States, Belgium and 6 more
- Volunteers
- 626 people
- Sponsor
- Cell Genesys
Prostate Cancer
A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
To compare the efficacy and safety of ASP3550 to goserelin acetate in patients with prostate cancer.
- Trial name
- NCT01964170
- Testing
- degarelix, Goserelin
- Where
- 8 sites in Japan
- Volunteers
- 234 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults
Flotufolastat F-18 Injection is a positron emission tomography (PET) imaging tracer that targets the extracellular domain of prostate-specific membrane antigen (PSMA).
- Trial name
- NCT07149831
- Testing
- Flotufolastat F-18 Injection
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Progressive Metastatic Castrate Resistant Prostate Cancer
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with…
- Trial name
- TulmiSTAR-01 (NCT07206056)
- Testing
- Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD
- Where
- 35 sites in United States, Australia and 12 more
- Volunteers
- 188 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer
This is a prospective, open-label, multicenter, Phase I/II exploratory diagnostic imaging study to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics, biodistribution, imaging characteristics, and…
- Trial name
- COPRA424 (NCT07765940)
- Testing
- [⁶⁴Cu]Cu-RAX301 Injection
- Volunteers
- 52 people
- Sponsor
- RadAlliance Therapeutics, Inc
Prostate Cancer Metastatic
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
This first-in-human, Phase 1/2, open-label study evaluates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of JSB462 (luxdegalutamide, previously ARV-766) administered as monotherapy and in…
- Trial name
- NCT05067140
- Testing
- ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone)
- Where
- 17 sites in United States
- Volunteers
- 164 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Metastatic Prostate Cancer
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
This is an open-label, randomized, parallel group two-stage phase 1-2 study with an escalation and an expansion component. This study will evaluate an extended-release (ER) formulation of onapristone in patients with prostate…
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT02049190
- Testing
- onapristone, abiraterone
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Arno Therapeutics
Metastatic Prostate Cancer
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
This is a study of opevesostat in healthy adult male participants. The purpose of this study is to understand the absorption, distribution, metabolism, and elimination of opevesostat in humans, as well as its pharmacokinetics…
- Trial name
- NCT06566989
- Testing
- [¹⁴C]Opevesostat, Prednisone, Fludrocortisone
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients.
- Trial name
- ARMOR2 (NCT01709734)
- Testing
- galeterone
- Where
- 23 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- LTN PHARMACEUTICALS, INC.
Metastatic Castration-Resistant Prostate Cancer
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide.
- Trial name
- NCT06318273
- Testing
- ABBV-969
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 152 people
- Sponsor
- AbbVie
Prostatic Neoplasms
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
- Trial name
- NCT02616185
- Testing
- PF-06755992, PF-06755990, TDS-IM Electroporation Device
- Where
- 19 sites in United States
- Volunteers
- 91 people
- Sponsor
- Pfizer
Prostatic Neoplasms
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
Evaluate the effect of darolutamide on the pharmacokinetics of a probe CYP3A4 substrate and Pgp substrate
- Trial name
- NCT03237416
- Testing
- Dabigatran etexilate, Midazolam, BAY1841788 (darolutamide)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bayer
Prostate Cancer, Rising Prostate Specific Antigen (PSA)
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer
- Trial name
- NCT02796898
- Testing
- SM88 (Cohort 1), SM88 (Cohort 2)
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Tyme, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.